Amiodarone Drug Classification
Amiodarone is classified as a Class III antiarrhythmic drug according to the Vaughan Williams classification, but it uniquely possesses electrophysiologic properties of all four antiarrhythmic drug classes. 1
Primary Classification
Amiodarone is formally designated as a Class III antiarrhythmic agent because its main effect with prolonged administration is to lengthen the cardiac action potential and prolong the QT interval through potassium channel blockade 2. This is the classification used by the FDA and major clinical guidelines 1.
Multi-Class Properties
What makes amiodarone unique among antiarrhythmic drugs is that it exhibits properties across all four Vaughan Williams classes 1:
- Class I effects: Blocks sodium channels at rapid pacing frequencies, slowing intracardiac conduction
- Class II effects: Exerts noncompetitive antisympathetic (beta-blocking) action, slowing heart rate
- Class III effects: Blocks myocardial potassium channels, prolonging refractoriness and action potential duration (primary mechanism)
- Class IV effects: Blocks calcium channels in nodal tissues, producing negative chronotropic effects similar to calcium channel blockers
Clinical Implications
This "broad spectrum" multi-class activity 1 explains why amiodarone affects multiple cardiac electrophysiologic parameters:
- Slows AV nodal conduction
- Prolongs AV nodal refractoriness
- Slows heart rate
- Prolongs QT interval
- Produces vasodilation
The drug is FDA-approved specifically for life-threatening ventricular arrhythmias 2, though it is widely used off-label for atrial fibrillation management 3.
Important Caveat
The complex pharmacology—combining effects of all four antiarrhythmic classes—contributes to amiodarone's high efficacy but also to its significant toxicity profile and numerous drug interactions, requiring careful monitoring during therapy 2.